Argyle Capital Partners’s AbbVie ABBV Stock Holding History

Argyle Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.93M	Sell	8,893 -4	-0%	-$887	1.39%	17
2025 Q4	$2.03M	Sell	8,897 -577	-6%	-$131K	1.49%	18
2025 Q3	$2.19M	Sell	9,474 -66	-0.7%	-$13.4K	1.57%	11
2025 Q2	$1.77M	Sell	9,540 -114	-1%	-$21.2K	1.46%	15
2025 Q1	$2.02M	Sell	9,654 -620	-6%	-$121K	1.73%	13
2024 Q4	$1.83M	Buy	+10,274	New	+$1.89M	1.57%	12

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Argyle Capital Partners's ABBV Position: Q1 2026 in Review

Argyle Capital Partners reduced its AbbVie (ABBV) stake by 0.04% in Q1 2026, selling an estimated $887 and leaving 8,893 shares worth $1.93M. The position accounts for 1.39% of the portfolio, ranked #17.

Argyle Capital Partners first reported a position in ABBV in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.19M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Argyle Capital Partners held 8,893 shares of AbbVie worth $1.93M as of Q1 2026.
Argyle Capital Partners sold 4 AbbVie shares in Q1 2026, an estimated $887.
AbbVie made up 1.39% of Argyle Capital Partners's portfolio in Q1 2026, its #17 holding.
Argyle Capital Partners first reported a position in AbbVie in Q4 2024 and has held it in 6 quarters since.
Argyle Capital Partners's AbbVie position peaked at $2.19M in Q3 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Argyle Capital Partners's 13F filing for Q1 2026, filed 7 May 2026.